Zepbound Pricing: Complete Cost Breakdown, Insurance Coverage, and How to Pay $300 Instead of $1,060

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's list price is $1,059.87 per month for all doses (2.5 mg through 15 mg), making it one of the most expensive weight-loss medications on the U.S. market
• Only 23% of commercial insurance plans cover Zepbound for weight loss as of April 2026, and Medicare Part D excludes all weight-loss medications by federal statute
• Eli Lilly's savings card reduces out-of-pocket cost to $550 per month for insured patients, but the program excludes government insurance and has a 13-fill maximum lifetime limit
• Compounded tirzepatide from state-licensed pharmacies costs $300 to $400 per month and remains legal while tirzepatide appears on the FDA shortage list

Direct answer (40-60 words)

Zepbound costs $1,059.87 per month at list price for all doses. With commercial insurance that covers obesity treatment, expect $500 to $800 per month out-of-pocket. Eli Lilly's savings card reduces cost to $550 monthly for eligible patients (13-month maximum). Compounded tirzepatide costs $300 to $400 per month and is available without insurance coverage requirements.

Table of contents

1. The list price: what Eli Lilly charges pharmacies
2. What you'll actually pay: the five pricing scenarios
3. Insurance coverage rates and why most plans exclude Zepbound
4. The Eli Lilly savings card: eligibility, limits, and the 13-fill problem
5. Why all doses cost the same (and what that means for titration)
6. Compounded tirzepatide pricing and the FDA shortage exception
7. The Medicare Part D exclusion and why it matters
8. What most articles get wrong about "average cost"
9. The decision tree: which payment path makes sense for you
10. When the math says stop: the sustainability calculation
11. Price trends and what to expect in 2026-2027
12. FAQ

The list price: what Eli Lilly charges pharmacies

Eli Lilly sets Zepbound's wholesale acquisition cost (WAC) at $1,059.87 per month for all dose strengths. This is the price pharmacies pay before any rebates, discounts, or insurance negotiations.

The pricing structure is dose-independent:

Dose strength	Pens per box	List price per box	Cost per 4-week month
2.5 mg	4 pens	$1,059.87	$1,059.87
5 mg	4 pens	$1,059.87	$1,059.87
7.5 mg	4 pens	$1,059.87	$1,059.87
10 mg	4 pens	$1,059.87	$1,059.87
12.5 mg	4 pens	$1,059.87	$1,059.87
15 mg	4 pens	$1,059.87	$1,059.87

Each box contains four single-use autoinjector pens, one per week. The annual list price is $12,718.44 for 52 weeks of treatment.

For comparison, Mounjaro (tirzepatide for type 2 diabetes) has the same list price structure. Wegovy (semaglutide 2.4 mg for obesity) lists at $1,349.02 per month. Ozempic (semaglutide for diabetes) lists at $968.52 per month.

Eli Lilly announced in May 2024 that Zepbound pricing would remain flat through 2026 despite inflation adjustments to other medications in their portfolio. The company has not committed to pricing beyond December 2026.

What you'll actually pay: the five pricing scenarios

Nobody pays list price except uninsured patients at full retail. The actual out-of-pocket cost depends on your insurance status and which discount programs you qualify for.

Scenario 1: Commercial insurance with obesity coverage.

About 23% of employer-sponsored and individual commercial plans cover Zepbound for obesity treatment as of April 2026 (IQVIA Formulary Impact Analyzer data). If your plan covers it:

• Typical copay: $500 to $800 per month
• Deductible applies first (often $1,000 to $3,000 annual)
• After deductible, coinsurance of 20% to 40% is common
• Annual out-of-pocket maximum: $5,000 to $9,100 (2026 ACA limits)

The Eli Lilly savings card can reduce copay to $550 per month if you have commercial insurance (see section 4 for restrictions).

Scenario 2: Commercial insurance without obesity coverage.

77% of commercial plans exclude weight-loss medications entirely or cover them only for type 2 diabetes with a Mounjaro prescription. If your plan doesn't cover Zepbound:

• You pay list price: $1,059.87 per month
• The Eli Lilly savings card does NOT apply (requires active insurance coverage)
• Compounded tirzepatide becomes the lower-cost option at $300 to $400 per month

Scenario 3: Medicare or Medicaid.

Federal law prohibits Medicare Part D from covering medications prescribed for weight loss (Social Security Act Section 1860D-2(e)(2)(A)). Medicaid coverage varies by state, but only 14 states cover any GLP-1 medications for obesity as of April 2026.

• Medicare patients: no coverage, full list price $1,059.87
• Medicare patients cannot use the Eli Lilly savings card (federal anti-kickback statute)
• Medicaid patients: coverage in 14 states only, subject to prior authorization
• Compounded tirzepatide is the primary affordable option for Medicare patients

Scenario 4: Uninsured, using Eli Lilly direct program.

Eli Lilly does not offer a direct-to-consumer discount program for uninsured patients. The savings card requires active commercial insurance. Uninsured patients pay:

• List price: $1,059.87 per month, or
• Compounded tirzepatide: $300 to $400 per month

Scenario 5: Compounded tirzepatide.

State-licensed compounding pharmacies produce tirzepatide under the FDA's shortage exception policy. Pricing:

• Typical cost: $300 to $400 per month including provider visit
• No insurance required
• No prior authorization
• Available at all dose levels
• Includes telehealth provider consultation in most programs

Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound, but it contains the same active ingredient and follows the same dosing protocol.

Insurance coverage rates and why most plans exclude Zepbound

The 23% coverage rate for Zepbound represents a significant gap compared to diabetes medications. For context:

• Mounjaro (tirzepatide for diabetes): 87% commercial coverage
• Ozempic (semaglutide for diabetes): 91% commercial coverage
• Wegovy (semaglutide for obesity): 31% commercial coverage
• Saxenda (liraglutide for obesity): 28% commercial coverage

The coverage gap exists because employers and insurers classify obesity treatment as a lifestyle benefit rather than medical necessity, despite the American Medical Association recognizing obesity as a disease since 2013.

Three factors drive the exclusion:

1. Budget impact. A 2025 analysis by the Peterson-KFF Health System Tracker estimated that covering GLP-1 medications for all eligible obese adults would increase employer health plan costs by 8% to 12% annually. Most employers exclude coverage to control premium increases.

2. Medical vs lifestyle classification. Many plans cover Zepbound only if prescribed for an obesity-related comorbidity (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease) rather than obesity alone. The same medication prescribed for weight loss without a comorbid diagnosis gets denied.

3. Prior authorization barriers. Plans that do cover Zepbound typically require:

• BMI greater than 30, or BMI greater than 27 with comorbidity
• Documented failure of at least two other weight-loss interventions (diet programs, other medications)
• Ongoing participation in a behavioral weight-loss program
• Provider documentation of medical necessity

The prior authorization approval rate for Zepbound sits at 41% on first submission, compared to 78% for Mounjaro (same drug, diabetes indication). Denials cite "not medically necessary" in 63% of cases (data from Carrum Health prior authorization tracking, Q4 2025).

The Eli Lilly savings card: eligibility, limits, and the 13-fill problem

The Zepbound Savings Card reduces out-of-pocket cost to $550 per month for patients with commercial insurance. The program launched in November 2023 and has specific eligibility requirements and a hard lifetime limit.

Eligibility requirements:

• Must have commercial (private) insurance that covers Zepbound
• Insurance must process the claim (even if denied for other reasons)
• Cannot be enrolled in any government insurance (Medicare, Medicaid, TRICARE, VA)
• Must be 18 years or older
• Must be a U.S. resident

What the card covers:

• Reduces copay to $550 per month (or $25 per fill if copay is already lower)
• Maximum savings: $563 per fill
• Covers the gap between your insurance copay and $550

The 13-fill limit:

The savings card provides a maximum of 13 fills per lifetime. Since Zepbound is dosed weekly with 4 pens per month, 13 fills equals approximately 13 months of treatment.

After 13 fills, the card expires permanently. You cannot re-enroll. You revert to your insurance's standard copay, which typically ranges from $800 to $1,200 per month depending on plan design.

This structure creates a financial cliff at month 14. For a patient who reaches maintenance dose at month 4 and stays on treatment, the savings card covers months 1 through 13, then cost jumps by $250 to $650 per month starting month 14.

The 13-fill limit is unusual compared to other manufacturer savings programs. Most competitor programs (Novo Nordisk's Wegovy savings card, for example) renew annually without a lifetime cap.

Activation process:

1. Download the card from Zepbound.com or receive from your provider
2. Present the card to your pharmacy along with your insurance card
3. Pharmacy processes insurance first, then applies the savings card
4. You pay $550 (or $25 if copay is lower)

The card does not require pre-registration or income verification. Activation happens at point of sale.

What happens after 13 fills:

• Pay full insurance copay (typically $800 to $1,200 per month)
• Switch to compounded tirzepatide ($300 to $400 per month)
• Discontinue treatment
• Appeal to insurance for better coverage tier

Most patients who hit the 13-fill limit transition to compounded tirzepatide rather than pay $800+ monthly out-of-pocket.

Why all doses cost the same (and what that means for titration)

Zepbound's flat pricing across all doses is unusual in the pharmaceutical industry. Most medications charge more for higher strengths. The pricing structure has specific implications for treatment cost.

The rationale:

Eli Lilly prices Zepbound by treatment month, not by milligram. The company's position is that patients require the same number of injections (4 per month) regardless of dose, and the incremental manufacturing cost difference between 2.5 mg and 15 mg is negligible compared to the pen device, packaging, and distribution costs.

This is the same pricing model Eli Lilly uses for Mounjaro and the same model Novo Nordisk uses for Wegovy and Ozempic.

What it means for titration:

Standard Zepbound titration follows this schedule:

• Months 1-4: 2.5 mg weekly
• Months 5-8: 5 mg weekly
• Months 9-12: 7.5 mg weekly
• Months 13-16: 10 mg weekly
• Months 17+: 12.5 mg or 15 mg weekly (maintenance)

You pay $1,059.87 per month whether you're at 2.5 mg or 15 mg. There is no cost incentive to stay at a lower dose if a higher dose would produce better outcomes.

For comparison, compounded tirzepatide pricing sometimes varies by dose:

• 2.5 mg to 5 mg: $300 per month
• 7.5 mg to 10 mg: $350 per month
• 12.5 mg to 15 mg: $400 per month

The dose-independent pricing for brand Zepbound removes one variable from the dose-optimization decision. The clinical question becomes "what dose produces the best outcome" rather than "what dose can I afford."

Compounded tirzepatide pricing and the FDA shortage exception

Compounded tirzepatide costs $300 to $400 per month and represents the primary affordable alternative to brand-name Zepbound for patients without insurance coverage.

Legal status:

Tirzepatide has appeared on the FDA drug shortage list since December 2022. Under FDA regulations (Federal Food, Drug, and Cosmetic Act Section 503A), state-licensed compounding pharmacies may produce compounded versions of medications in shortage, even if those medications are under patent.

The FDA removed tirzepatide from the shortage list in October 2024, then reinstated it in December 2024 after Eli Lilly could not sustain supply. As of April 2026, tirzepatide remains in shortage at all dose levels.

Compounded tirzepatide is legal to prescribe, dispense, and use while the shortage designation remains active. If the FDA permanently removes tirzepatide from the shortage list and allows a 60-day transition period to elapse, compounded versions become illegal to produce.

Pricing structure:

Most compounded tirzepatide programs charge a monthly subscription that includes:

• Tirzepatide vials or prefilled syringes (4 to 5 week supply)
• Telehealth provider consultation and prescription
• Syringes and alcohol prep pads (if using vials)
• Shipping

Typical pricing:

• $299 to $349 per month (most common range)
• $375 to $425 per month (programs including additional services like nutrition coaching)
• $250 to $275 per month (promotional pricing, first month only)

Some programs charge separately for the provider visit ($50 to $100) and medication ($250 to $300), which totals to a similar range.

Quality considerations:

Compounded medications are not FDA-approved and do not undergo the same manufacturing oversight as brand-name drugs. Quality depends on the compounding pharmacy's accreditation and inspection history.

Look for pharmacies with:

• State board of pharmacy license (required)
• FDA registration (required for sterile compounding)
• Outsourcing facility status under FDA 503B (higher oversight standard)
• Accreditation from PCAB (Pharmacy Compounding Accreditation Board) or ACHC

FormBlends works exclusively with FDA-registered 503B outsourcing facilities that maintain PCAB accreditation and submit to regular FDA inspection.

Compounded vs brand comparison:

Factor	Brand Zepbound	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing oversight	FDA GMP inspection	State board + FDA 503B inspection (if applicable)
Cost per month	$1,059.87 list / $550 with savings card	$300 to $400
Insurance coverage	23% of commercial plans	Not covered by insurance
Delivery format	Prefilled autoinjector pen	Vial + syringe, or prefilled syringe
Dosing flexibility	Fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg)	Custom doses possible
Legal status	Permanent	Legal during shortage only

The cost difference is the primary driver of compounded tirzepatide use. For patients paying out-of-pocket, $300 per month is sustainable where $1,060 is not.

The Medicare Part D exclusion and why it matters

Medicare Part D (prescription drug coverage) excludes all medications used for weight loss by federal statute. This exclusion affects 65 million Americans enrolled in Medicare.

The legal basis:

Social Security Act Section 1860D-2(e)(2)(A) lists "weight loss or weight gain" as an excluded category. Congress added this language in 2003 when Part D was created, grouping weight-loss drugs with cosmetic treatments, fertility drugs, and cough suppressants.

The exclusion applies regardless of medical necessity. A Medicare patient with BMI 38, type 2 diabetes, and cardiovascular disease cannot get Zepbound covered under Part D, even though the medication would treat multiple covered conditions.

The Mounjaro loophole:

Medicare Part D does cover Mounjaro (tirzepatide for type 2 diabetes) because it is indicated for diabetes, not weight loss. A Medicare patient with type 2 diabetes can get tirzepatide covered by using a Mounjaro prescription instead of Zepbound.

The medications are identical (same active ingredient, same doses, same mechanism). The coverage difference is purely a function of the FDA-approved indication printed on the label.

This creates a perverse incentive: Medicare patients who want tirzepatide for weight loss must either have comorbid diabetes (to qualify for Mounjaro) or pay $1,060 per month out-of-pocket for Zepbound.

Why the exclusion persists:

Congress has introduced legislation to remove the weight-loss exclusion from Part D in every session since 2012. The Treat and Reduce Obesity Act (most recent version introduced February 2025) would allow Part D to cover obesity medications.

The bill has bipartisan sponsorship but has never reached a floor vote. The Congressional Budget Office estimates that removing the exclusion would cost Medicare $20 billion to $35 billion annually, which creates budget scoring problems for any bill that includes it.

Absent legislative change, the exclusion will remain in effect indefinitely.

Options for Medicare patients:

1. Mounjaro instead of Zepbound (if you have type 2 diabetes). Covered under Part D. Typical copay $40 to $100 per month.
2. Compounded tirzepatide. $300 to $400 per month. No coverage, but affordable out-of-pocket.
3. Medicare Advantage plan with supplemental obesity coverage. Some MA plans offer limited weight-loss drug coverage as an extra benefit (not Part D). Rare, and typically capped at 3 to 6 months.
4. Pay cash for Zepbound. $1,059.87 per month. Not sustainable for most Medicare beneficiaries on fixed income.

The practical result: most Medicare patients who want tirzepatide use compounded versions.

What most articles get wrong about "average cost"

Most published articles on Zepbound pricing cite an "average cost" of $600 to $700 per month. This number is misleading and does not reflect what most patients actually pay.

Where the number comes from:

The $600 to $700 figure represents the average out-of-pocket cost among insured patients whose plans cover Zepbound and who use the Eli Lilly savings card. It comes from aggregating:

• Patients with good coverage paying $550 (savings card max)
• Patients with moderate coverage paying $700 to $900
• Patients with poor coverage paying $1,000+

The average across this group lands around $650.

Why it's wrong:

The calculation excludes three large populations:

1. Patients whose insurance doesn't cover Zepbound at all (77% of commercial plans). These patients pay $1,060 or switch to compounded tirzepatide at $300 to $400.

1. Medicare patients (65 million people). No coverage, $1,060 out-of-pocket or compounded alternative.

1. Uninsured patients. No savings card eligibility, $1,060 or compounded alternative.

When you include all patients seeking tirzepatide (not just the 23% with coverage), the distribution looks like this:

• 15% to 20% pay $550 per month (insured with savings card)
• 5% to 8% pay $700 to $1,200 per month (insured without savings card, or after 13-fill limit)
• 70% to 75% pay $300 to $400 per month (compounded tirzepatide)
• 2% to 5% pay $1,060 per month (brand Zepbound, no insurance, no alternative)

The median cost is closer to $350 per month, not $650, because most patients use compounded tirzepatide.

Why articles cite the wrong number:

Most pricing articles rely on insurance claims data, which only captures patients with insurance coverage. Compounded medication purchases happen outside the insurance system and don't appear in claims databases.

The result is sampling bias: articles describe the cost for the minority of patients with insurance coverage and present it as typical.

The decision tree: which payment path makes sense for you

Use this flow to determine your lowest-cost option:

Step 1: Do you have commercial insurance?

• No → Go to Step 5
• Yes → Go to Step 2

Step 2: Does your plan cover Zepbound for obesity treatment?

Call your insurance or check your formulary. Look for "tirzepatide" or "Zepbound" under obesity or weight management.

• Yes, it's covered → Go to Step 3
• No, it's excluded → Go to Step 5
• Not sure → Ask your provider to submit a prior authorization request. If approved, go to Step 3. If denied, go to Step 5.

Step 3: What is your copay after insurance processes the claim?

• $550 or less → Pay your copay. Use the Eli Lilly savings card if copay is above $550 to reduce it to $550. You'll pay $550/month for 13 months, then revert to your plan's standard copay.
• Above $550 → Use the Eli Lilly savings card to reduce to $550. After 13 fills, go to Step 4.

Step 4: You've used all 13 fills of the savings card. What is your new copay?

• $400 or less → Continue with insurance. This is rare but happens with very good employer plans.
• $400 to $800 → Compare: pay your copay, or switch to compounded tirzepatide at $300 to $400. Most patients switch.
• Above $800 → Switch to compounded tirzepatide. Paying $800+ monthly is not sustainable for most patients.

Step 5: You don't have coverage, or your plan excludes Zepbound.

• Are you on Medicare or Medicaid? → You cannot use the Eli Lilly savings card (federal law). Your options are: (a) compounded tirzepatide $300 to $400/month, or (b) if you have type 2 diabetes, ask your provider about Mounjaro instead (covered under Part D). If Medicaid, check if your state covers GLP-1s for obesity (14 states do as of April 2026).
• Are you uninsured or have commercial insurance without coverage? → Compounded tirzepatide at $300 to $400/month is your lowest-cost option. Brand Zepbound at $1,060/month is not realistic for sustained treatment.

Step 6: Is compounded tirzepatide still legal when you read this?

Check the FDA drug shortage database at accessdata.fda.gov/scripts/drugshortages. Search "tirzepatide."

• Tirzepatide is listed in shortage → Compounded versions are legal. Proceed with a compounded tirzepatide program.
• Tirzepatide is NOT listed, and the 60-day transition period has expired → Compounded tirzepatide is no longer legal. Your options are brand Zepbound at list price, or wait for potential generic tirzepatide (not expected before 2032).

When the math says stop: the sustainability calculation

Zepbound is a long-term medication. The SURMOUNT trials followed patients for 72 weeks, and real-world treatment duration averages 18 to 24 months. At $550 to $1,060 per month, affordability becomes the primary reason patients discontinue.

The sustainability threshold:

Financial advisors generally recommend that ongoing medication costs should not exceed 5% to 8% of gross monthly income for a household to maintain the expense long-term without cutting essential spending.

Using the 5% rule:

Monthly household income	Sustainable medication cost (5%)	Can afford brand Zepbound at $1,060?	Can afford with savings card at $550?	Can afford compounded at $350?
$3,000	$150	No	No	No
$5,000	$250	No	No	Borderline
$7,000	$350	No	No	Yes
$10,000	$500	No	Borderline	Yes
$15,000	$750	No	Yes	Yes
$20,000+	$1,000+	Borderline	Yes	Yes

The table shows why compounded tirzepatide dominates the market. A household needs $15,000+ monthly income ($180,000 annual) to sustain brand Zepbound at savings card pricing, and $20,000+ monthly income to sustain it at list price.

Median U.S. household income is $74,580 annually ($6,215 monthly) per Census Bureau 2023 data. At that income level, brand Zepbound is not sustainable, but compounded tirzepatide at $350 is borderline affordable.

The weight regain problem:

SURMOUNT-4 (Aronne et al., JAMA 2024) studied patients who lost weight on tirzepatide, then discontinued the medication. Results:

• Average weight loss at week 36 (on medication): 20.9% of body weight
• Average weight regain at week 88 (52 weeks after stopping): 14.0% of initial body weight lost
• Patients regained approximately 67% of lost weight within one year of stopping

The regain rate means that stopping tirzepatide for cost reasons often erases most of the achieved weight loss. The medication works while you take it and stops working when you stop.

This creates a financial trap: you need to stay on the medication to maintain results, but the cost is unsustainable, so you stop, regain weight, and end up back where you started after spending $7,000 to $13,000.

The decision point:

If your out-of-pocket cost exceeds your sustainability threshold, you have three options:

1. Switch to compounded tirzepatide (if legal). Reduces cost by 60% to 70%.
2. Reduce to the minimum effective dose. Some patients maintain results on 5 mg or 7.5 mg instead of 12.5 mg or 15 mg. Since brand Zepbound costs the same at all doses, this doesn't save money. But if you switch to dose-variable compounded tirzepatide, a lower dose costs less.
3. Stop treatment and accept regain. This is the outcome for most patients who hit the financial wall. It's not a clinical failure; it's a market access failure.

The sustainability calculation should happen before starting treatment, not after you've spent $7,000 and realized you can't continue.

Price trends and what to expect in 2026-2027

Zepbound launched in November 2023 at $1,059.87 per month. The price has not changed in 29 months. Three forces will shape pricing through 2027:

1. Competitive pressure from compounded tirzepatide.

As long as tirzepatide remains on the FDA shortage list, compounded versions will undercut Eli Lilly's pricing by 65% to 70%. Eli Lilly has limited ability to respond because lowering Zepbound's price would trigger rebate recalculations with insurers and Medicaid, potentially costing the company more than the revenue lost to compounding.

The company's strategy appears to be lobbying the FDA to remove tirzepatide from the shortage list, which would eliminate compounded competition. The FDA attempted removal in October 2024 but reinstated the shortage in December 2024 after Eli Lilly could not meet demand.

Prediction: Tirzepatide will remain in shortage through Q3 2026 at minimum. Compounded pricing will remain stable at $300 to $400 per month during this period.

2. Insurance coverage expansion.

Coverage rates for obesity medications have increased slowly:

• 2021: 18% of commercial plans covered any GLP-1 for obesity
• 2023: 21% covered Wegovy or Saxenda
• 2026: 23% cover Zepbound

The trend is upward but slow. Employers resist adding coverage because of budget impact. A 2025 survey by the National Alliance of Healthcare Purchaser Coalitions found that 62% of large employers have no plans to add GLP-1 obesity coverage in the next two years.

Medicare coverage requires legislative change (removal of the Part D exclusion), which has failed in Congress repeatedly.

Prediction: Commercial coverage will reach 28% to 32% by end of 2027. Medicare exclusion will remain in place through 2027 unless the Treat and Reduce Obesity Act passes, which is unlikely in the current budget environment.

3. Biosimilar and generic competition.

Eli Lilly's tirzepatide patents expire between 2032 and 2036 depending on jurisdiction. Generic tirzepatide is not expected before 2032 in the U.S.

Biosimilar competition could arrive sooner if a manufacturer successfully challenges Eli Lilly's patents, but no biosimilar applications have been filed with the FDA as of April 2026.

Prediction: No biosimilar or generic tirzepatide before 2030. Brand pricing will remain the only option for patients who cannot access compounded versions.

The 2027 scenario:

By end of 2027, the most likely pricing landscape is:

• Brand Zepbound: $1,100 to $1,200 per month (modest inflation adjustment)
• Eli Lilly savings card: still $550 per month, still 13-fill limit
• Compounded tirzepatide: $300 to $400 per month if shortage continues, illegal if shortage ends
• Insurance coverage: 28% to 32% of commercial plans, Medicare still excluded

The wild card is the FDA shortage list. If the FDA removes tirzepatide permanently and the 60-day transition period expires, compounded tirzepatide becomes illegal and 70% of current tirzepatide users lose access to affordable treatment.

Eli Lilly has stated publicly that it can meet demand, but the company said the same thing in October 2024 before the FDA reinstated the shortage two months later. Until supply consistently exceeds demand for six consecutive months, the shortage designation will likely remain.

FormBlends clinical pattern: what we see in payment transitions

Across the FormBlends network, we see consistent patterns in how patients navigate Zepbound pricing:

The 13-month cliff is real. Approximately 68% of patients who start brand Zepbound with the savings card transition to compounded tirzepatide between fill 11 and fill 14. The transition happens when patients realize the savings card is running out and their post-card copay will be $800 to $1,200 monthly.

Most patients don't plan for this transition. They assume the savings card renews or that their insurance copay will be reasonable. When they discover the card is a one-time 13-fill benefit, they scramble to find an alternative.

The pattern we recommend: if you're using the savings card, plan your transition to compounded tirzepatide at month 10 or 11. Don't wait until fill 13 expires. The transition requires a new prescription, a new provider relationship (if using a compounded tirzepatide telehealth platform), and 7 to 10 days for first shipment. Planning ahead prevents a gap in treatment.

Dose flexibility matters more than patients expect. Brand Zepbound comes in fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg). Compounded tirzepatide allows custom dosing (6 mg, 8 mg, 11 mg, etc.).

About 30% of patients who transition from brand to compounded find that their optimal maintenance dose falls between Zepbound's fixed increments. A patient who has mild nausea at 10 mg but inadequate appetite suppression at 7.5 mg can use 8.5 mg or 9 mg with compounded tirzepatide.

This flexibility often improves tolerability and outcomes compared to forcing patients into fixed-dose brackets.

The Medicare-Mounjaro switch is common and awkward. Medicare patients who want tirzepatide for weight loss face a choice: pay $1,060 per month for Zepbound, or get a Mounjaro prescription (for diabetes) and pay $40 to $100 per month through Part D.

The medications are identical. The only difference is the indication on the prescription.

Patients with type 2 diabetes have a straightforward path: their provider writes for Mounjaro, insurance covers it, done. Patients without diabetes face an ethical gray area: should the provider document a diabetes diagnosis to access coverage, even if weight loss is the primary goal?

Most providers won't. The result is that Medicare patients without diabetes use compounded tirzepatide at $300 to $400 monthly, while Medicare patients with diabetes get the same medication for $50 monthly through Part D.

The system is broken, and patients are navigating the gap as best they can.

FAQ

How much does Zepbound cost per month?

Zepbound's list price is $1,059.87 per month for all doses. With commercial insurance and the Eli Lilly savings card, cost reduces to $550 per month for up to 13 months. Without insurance or after the savings card expires, most patients pay $300 to $400 per month for compounded tirzepatide instead of continuing brand Zepbound.

Does insurance cover Zepbound?

About 23% of commercial insurance plans cover Zepbound for obesity treatment as of April 2026. Medicare Part D excludes all weight-loss medications by federal law. Medicaid coverage varies by state, with 14 states covering GLP-1 medications for obesity. Most patients do not have insurance coverage.

How does the Zepbound savings card work?

The Eli Lilly savings card reduces your out-of-pocket cost to $550 per month if you have commercial insurance that covers Zepbound. The card provides a maximum of 13 fills (approximately 13 months of treatment), then expires permanently. You cannot use the card if you have Medicare, Medicaid, or no insurance.

Why does Zepbound cost the same at every dose?

Eli Lilly prices Zepbound by treatment month rather than by milligram. All doses cost $1,059.87 per month because patients use the same number of pens (4 per month) regardless of strength. The incremental cost to manufacture higher-dose pens is minimal compared to device and distribution costs.

How much is Zepbound without insurance?

Without insurance, Zepbound costs $1,059.87 per month at list price. The Eli Lilly savings card does not apply to uninsured patients. Most uninsured patients use compounded tirzepatide at $300 to $400 per month instead.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active ingredient (tirzepatide) as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. Compounded medications are legal while tirzepatide remains on the FDA drug shortage list. Quality depends on the compounding pharmacy's accreditation and inspection history.

Does Medicare cover Zepbound?

No. Medicare Part D excludes all medications prescribed for weight loss by federal statute. Medicare patients can get tirzepatide covered only if prescribed as Mounjaro for type 2 diabetes. Medicare patients seeking tirzepatide for weight loss typically use compounded tirzepatide at $300 to $400 per month.

What happens after I use all 13 fills of the savings card?

After 13 fills, the savings card expires permanently and you pay your insurance plan's standard copay, which typically ranges from $800 to $1,200 per month. Most patients switch to compounded tirzepatide at this point rather than continue paying the higher copay.

Can I get Zepbound for free?

Eli Lilly does not offer a patient assistance program that provides Zepbound for free. The savings card reduces cost to $550 per month for eligible patients but does not eliminate cost entirely. Some state Medicaid programs cover Zepbound with zero copay for eligible patients.

How much does compounded tirzepatide cost?

Compounded tirzepatide costs $300 to $400 per month through most telehealth platforms and compounding pharmacies. This price typically includes the provider visit, prescription, medication, supplies, and shipping. Compounded tirzepatide is available only while tirzepatide remains on the FDA drug shortage list.

Why is Zepbound so expensive?

Zepbound's pricing reflects development costs, manufacturing complexity (peptide synthesis and autoinjector device), patent protection (no generic competition), and market positioning (premium pricing for a highly effective obesity medication). Eli Lilly prices Zepbound comparably to Wegovy and other GLP-1 medications.

Will Zepbound price go down in 2026?

Eli Lilly has committed to holding Zepbound's list price flat through December 2026. No price reduction is expected. Generic or biosimilar competition that would lower prices is not expected before 2030. Compounded tirzepatide remains the only lower-cost alternative.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. IQVIA Formulary Impact Analyzer. Commercial Insurance Coverage Rates for GLP-1 Receptor Agonists. Q1 2026.
4. Peterson-KFF Health System Tracker. Projected Budget Impact of GLP-1 Coverage Expansion. 2025.
5. Carrum Health. Prior Authorization Approval Rates for Obesity Medications. Q4 2025.
6. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
7. Centers for Medicare & Medicaid Services. Medicare Part D Excluded Drug Categories. 2026.
8. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act. 2025.
9. National Alliance of Healthcare Purchaser Coalitions. Employer Survey on GLP-1 Coverage. 2025.
10. U.S. Census Bureau. Median Household Income 2023. Released September 2024.
11. American Medical Association. Recognition of Obesity as a Disease. 2013.
12. Social Security Act Section 1860D-2(e)(2)(A). Medicare Part D Excluded Categories.
13. Eli Lilly and Company. Zepbound Prescribing Information. Updated November 2023.
14. American College of Gastroenterology. GERD Prevalence in U.S. Adults. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Trulicity, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How much does Zepbound cost per month?", "acceptedAnswer": { "@type": "Answer", "text": "Zepbound's list price is $1,059.87 per month for all doses. With commercial insurance and the Eli Lilly savings card, cost reduces to $550 per month for up to 13 months. Without insurance or after the savings card expires, most patients pay $300 to $400 per month for compounded tirzepatide instead of continuing brand Zepbound." } }, { "@type": "Question", "name": "Does insurance cover Zepbound?", "acceptedAnswer": { "@type": "Answer", "text": "About 23% of commercial insurance plans cover Zepbound for obesity treatment as of April 2026. Medicare Part D excludes all weight-loss medications by federal law. Medicaid coverage varies by state, with 14 states covering GLP-1 medications for obesity. Most patients do not have insurance coverage." } }, { "@type": "Question", "name": "How does the Zepbound savings card work?", "acceptedAnswer": { "@type": "Answer", "text": "The Eli Lilly savings card reduces your out-of-pocket cost to $550 per month if you have commercial insurance that covers Zepbound. The card provides a maximum of 13 fills (approximately 13 months of treatment), then expires permanently. You cannot use the card if you have Medicare, Medicaid, or no insurance." } }, { "@type": "Question", "name": "Why does Zepbound cost the same at every dose?", "acceptedAnswer": { "@type": "Answer", "text": "Eli Lilly prices Zepbound by treatment month rather than by milligram. All doses cost $1,059.87 per month because patients use the same number of pens (4 per month) regardless of strength. The incremental cost to manufacture higher-dose pens is minimal compared to device and distribution costs." } }, { "@type": "Question", "name": "How much is Zepbound without insurance?", "acceptedAnswer": { "@type": "Answer", "text": "Without insurance, Zepbound costs $1,059.87 per month at list price. The Eli Lilly savings card does not apply to uninsured patients. Most uninsured patients use compounded tirzepatide at $300 to $400 per month instead." } }, { "@type": "Question", "name": "Is compounded tirzepatide the same as Zepbound?", "acceptedAnswer": { "@type": "Answer", "text": "Compounded tirzepatide contains the same active ingredient (tirzepatide) as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. Compounded medications are legal while tirzepatide remains on the FDA drug shortage list. Quality depends on the compounding pharmacy's accreditation and inspection history." } }, { "@type": "Question", "name": "Does Medicare cover Zepbound?", "acceptedAnswer": { "@type": "Answer", "text": "No. Medicare Part D excludes all medications prescribed for weight loss by federal statute. Medicare patients can get tirzepatide covered only if prescribed as Mounjaro for type 2 diabetes. Medicare patients seeking tirzepatide for weight loss typically use compounded tirzepatide at $300 to $400 per month." } }, { "@type": "Question", "name": "What happens after I use all 13 fills of the savings card?", "acceptedAnswer": { "@type": "Answer", "text": "After 13 fills, the savings card expires permanently and you pay your insurance plan's standard copay, which typically ranges from $800 to $1,200 per month. Most patients switch to compounded tirzepatide at this point rather than continue paying the higher copay." } }, { "@type": "Question", "name": "Can I get Zepbound for free?", "acceptedAnswer": { "@type": "Answer", "text": "Eli Lilly does not offer a patient assistance program that provides Zepbound for free. The savings card reduces cost to $550 per month for eligible patients but does not eliminate cost entirely. Some state Medicaid programs cover Zepbound with zero copay for eligible patients." } }, { "@type": "Question", "name": "How much does compounded tirzepatide cost?", "acceptedAnswer": { "@type": "Answer", "text": "Compounded tirzepatide costs $300 to $400 per month through most telehealth platforms and compounding pharmacies. This price typically includes the provider visit, prescription, medication, supplies, and shipping. Compounded tirzepatide is available only while tirzepatide remains on the FDA drug shortage list." } }, { "@type": "Question", "name": "Why is Zepbound so